Investigating psychiatric and cognitive traits in specific genetic syndromes
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors
This study is testing how certain medications can help improve mental and thinking skills in people with Velocardiofacial Syndrome, Williams Syndrome, and Fragile X Syndrome.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Sex | All |
| Sponsor | The Chaim Sheba Medical Center Academic / other |
| Locations | 1 site (Petah Tikva) |
| Trial ID | NCT00768820 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the psychiatric and cognitive phenotypes associated with Velocardiofacial Syndrome, Williams Syndrome, and Fragile X Syndrome. It involves administering treatments such as methylphenidate, fluoxetine, and risperidone to assess their effects on these phenotypes. The research will also examine the connections between these traits and developmental as well as molecular factors. By characterizing these conditions, the study seeks to enhance understanding and treatment options for affected individuals.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Velocardiofacial Syndrome, Williams Syndrome, or Fragile X Syndrome who have a proven chromosomal deletion.
Not a fit: Patients without a confirmed chromosomal deletion or those with other unrelated psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with these genetic syndromes.
How similar studies have performed: While there have been studies on the cognitive and psychiatric aspects of these syndromes, this particular approach focusing on treatment effects is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * chromosomal deletion proven by FISH examination Exclusion Criteria:
Where this trial is running
Petah Tikva
- Schneider Children's Mediac Center of Israel — Petah Tikva, Israel (Recruiting)
Study contacts
- Study coordinator: Doron Gothelf, MD
- Email: gothelf@post.tau.ac.il
- Phone: 972-03-5302663
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.